Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Boston Scientific (BSX) concluded the recent trading session at $72.99, signifying a +1.08% move from its prior day's close.
Boston Scientific Corporation (BSX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The latest trading day saw Boston Scientific (BSX) settling at $76.85, representing a +1.45% change from its previous close.
Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Alliance Wealth Advisors LLC UT increased its position in Boston Scientific Corporation (NYSE: BSX) by 207.7% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 16,560 shares of the medical equipment provider's stock after purchasing an additional 11,178 shares during the period. Alliance Wealth Advisors LLC
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
Boston Scientific BSX reported its fourth-quarter 2025 results on Feb. 4. Both top and bottom lines exceeded the company's guidance ranges and topped the respective Zacks Consensus Estimate.
On Wednesday, Boston Scientific (BSX) experienced a loss of nearly one-fifth of its market capitalization in a single trading session. The stock finished at $75.50, reaching a 52-week low, with a volume approximately six times greater than the 3-month average.
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market.
Boston Scientific (BSX), a leading global player in medical devices, announced solid Q4 earnings but offered 2026 guidance that slightly fell short of elevated investor expectations. This response was marked by a drastic, high-volume liquidation event that quickly erased months of gains.